A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

NCT07288580 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Interventions

DRUG: EHT102 Injection

Sponsor

Shanghai Euhearing Therapeutics Co., Ltd